Recruiting
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE): More InformationActive, not recruiting
The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of
For Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma: More InformationActive, not recruiting
The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the
For Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression: More InformationThe purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and
For Patients With Recurrent Malignant Glioma: More InformationThe safety and efficacy of the investigational use of this product has not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.
